Lactose Intolerance Treatment Market is expected to witness a moderate growth at a CAGR of 7.2 % from 2017-2023

global Lactose Intolerance Treatment Market is growing at a rate of 7.2 % and is expected show a similar trend during the forecast period.

Major Key Players are Johnson & Johnson Inc.,National Enzyme Company, Vetbiochem India Private Limited, Scimera Partners, Ganeden Biotech, Daiya Foods Inc., ”

— Market Research Future

PUNE, MAHARASHTRA, INDIA, July 24, 2017 /EINPresswire.com/ — Market Highlights

The lactose intolerance treatment market is chiefly driven by rise in awareness and greater screening rates in the world and especially in the developed regions of North America and Europe. The exact number of people with lactose intolerance is unknown but it is estimated that about 65% of the global population suffers from lactate intolerance. It is also estimated that lactate intolerance rates vary from less than 10% in Northern Europe to as high as 95% in parts of Asia and Africa.

Lactose intolerance can also be managed by consuming live yogurt cultures containing lactobacilli and other milk fermentation products which explains why many people, though genetically lactose intolerant, are able to tolerate large quantities of milk. Plant-based milks such as soy milk, rice milk, coconut milk, oat milk, etc. are inherently lactose-free. Low-lactose or lactose-free versions of foods supplements are used for those patients who have high lactose intolerance. Patients with little or no lactase enzyme can be supplemented by artificially produced from microbes of genus Aspergillus. The enzyme, β-galactosidase, is used and is available over the counter in many countries.

Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/3868

The food supplements dominate the segment for treatment and are led by products such as Lactose free dairy products. Rising awareness and increasing health expenditures is a strong driver for the market for lactose intolerance treatment. Breast milk substitutes are another products which are used if breast feeding is not possible in infants with severe lactose intolerance. The breast milk substitutes products are fortified with dietary nutrients such as iron, vitamins etc. Vegetable products such as soy-based or rice-based infant milks are also available which is strengthening the market for lactose intolerance treatment.

Major Market Players:

• Johnson & Johnson Inc.,
• National Enzyme Company,
• Vetbiochem India Private Limited,
• Scimera Partners,
• Ganeden Biotech,
• Daiya Foods Inc.,
• Arla Foods,
• McNeil Nutritionals,
• Oberland-Milchverwertung (OMIRA),
• Parmalat, Valio

Test the market data and market information presented through more than 50 market data tables and figures spread over 80 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Lactose intolerance treatment Market Research Report – Forecast to 2023.”

Report Details @ https://www.marketresearchfuture.com/reports/lactose-intolerance-treatment-market-3868

Segmentation:

The global lactose intolerance treatment market is segmented on the basis of type, treatment and end users. Based on type, the market has been segmented as primary, secondary, developmental and congenital. Based on the treatment, the market has been segmented as food supplements (dairy, milk substitutes (soy, rice, coconut, almond, others), cereals and breads, fats, others), enzymatic lactase supplements, and others. Based on the end users, the market has been segmented as hospitals and clinics, home use, and others.

Table of Content

1. Introduction
1.1 Definition
1.2 Scope Of Study
1.2.1 Research Objective
1.2.2 Assumptions & Limitations
1.2.2.1 Assumptions
1.2.2.2 Limitations
1.3 Market Structure:
2. Research Methodology
2.1 Research Process:
2.2 Primary Research
2.3 Secondary Research:
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Macroeconomic Indicators
4. Market Factor Analysis
4.1 Porters Five Forces Model
4.2 Bargaining Power Of Suppliers
4.3 Bargaining Power Of Buyers
Continued….

Browse Related Statistical Report

Asia pacific Insulin Pump Market is projected to grow at a CAGR of 8.9% and is expected to reach US$ 1,323.6 million by 2023. In Asia pacific Insulin Pump Market, Japan accounted for the largest market share in 2016.

https://www.marketresearchfuture.com/statistical-reports/asia-pacific-insulin-pump-market-3693

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact:
Akash Anand,
Market Research Future
+1 646 845 9312
Email: akash.anand@marketresearchfuture.com

Akash Anand
Market Research Future
+1-646-845-9349 (US) / +44 208 133 9349 (UK)
email us here


Source: EIN Presswire

Keratoconus Treatment Market Is Growing Continuously and Expected To Grow At A CAGR Of 4.1% From 2017 To 2023

Keratoconus treatment market information, by type (Forme Fruste keratoconus, Corneal Hydrops)by diagnosis, by treatment, by end user- global forecast till 2023

Major Key Players are Bausch & Lomb Incorporated (US), CIBA VISION (US), CooperVision (US), HOYA Vision Care (Singapore),Johnson & Johnson Vision Care, Inc. (US), Menicon Co., Ltd. (Japan), ”

— Market Research Future

PUNE, MAHARASHTRA, INDIA, July 24, 2017 /EINPresswire.com/ — Market Highlights

The global keratoconus treatment market has been evaluated as a rapidly growing market and it is expected to continue growing in the near future.

Approximately 3 million people are affected by this disease across the globe. Advanced diagnostic and treatment options are key drivers for this market. Increasing awareness of the disease, increasing funding for R&D and growing demand from emerging regions such as Asia are major driving forces of the market. Major players of this market are investing in R&D to develop effective solution for keratoconus. Introduction of wide range of lenses is important factor for market growth.

The market for keratoconus treatment was around USD 322.7 million in 2016 and is expected to reach USD 427.5 million by 2023 which is a projected CAGR of 4.1%.

Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/3861

Major Key Players:

• Bausch & Lomb Incorporated (US),
• CIBA VISION (US),
• CooperVision (US),
• HOYA Vision Care (Singapore),
• Johnson & Johnson Vision Care, Inc. (US),
• Menicon Co., Ltd. (Japan),
• Novartis AG (Switzerland),
• Optik Seis (Indonesia),
• SAFILENS S.R.L. (Italy),

Regional Analysis:

Considering the global scenario of the keratoconus treatment market, there are four main regions, the Americas, Europe, Asia Pacific, and Middle East and Africa.
The Americas is dominating region in global keratoconus treatment market. Mainly US is highest revenue generator and important contributor in this market. Technological advancement and rapid adoption of new treatments and products are driving the growth for this market. European market is second largest and is growing significantly. Germany is holding highest market share in this market that is mainly due to investment in R&D and new product development. Due to increasing awareness of disease, adoption of new products, and increasing purchasing capacity, Asia Pacifies is fastest growing market while China is highest revenue generator in this region. Middle East & Africa is expected to have limited growth. Middle Eastern countries are growing significantly and dominating this market.

Taste the market data and market information presented through more than 56 market data tables and figures spread over 80 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Keratoconus Treatment Market Research Report–Global Forecast to 2023.”

Report Details @ https://www.marketresearchfuture.com/reports/keratoconus-treatment-market-3861

Segmentation:

Global keratoconus treatment market has been segmented on the basis of type which comprises of forme fruste keratoconus, corneal hydrops, keratoglobus, pellucid marginal degeneration, posterior keratoconus, and others.
On the basis of diagnosis, the market is segmented into computerized corneal mapping, keratometry, slit-lamp examination, refraction test, and others. Slit-lamp examination includes tonometry, vision testing, and others.

On the basis of treatments, the market has been segmented into lenses, surgery, collagen cross-linking, and others. Lenses is sub-segmented into eyeglasses or soft contact lenses, hard contact lenses, piggyback lenses, hybrid lenses, scleral lenses, and others. Surgery sub-segmented into corneal inserts, cornea transplant, and others. Collagen cross-linking is still in research process and more study required implementing this treatment option.

On the basis of end user, it is segmented into eye hospitals & clinics, medical research centers, academic institutes, and others.

Table of Content

1. Report Prologue
2. Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
2.3 Market Structure
2.4. Market Segmentation
3. Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Mega Trends
4.5 Macroeconomic Indicators
5. Market Factor analysis
Continued….

Browse Related Statistical Report

Europe Insulin Pump Market is projected to grow at a CAGR of 8.7% and is expected to reach US$ 2,784.5 million by 2023. In Europe Insulin Pump Market, Germany accounted for the largest market share in 2016.

https://www.marketresearchfuture.com/statistical-reports/europe-insulin-pump-market-3694

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact:
Akash Anand,
Market Research Future
+1 646 845 9312
Email: akash.anand@marketresearchfuture.com

Akash Anand
Market Research Future
+1-646-845-9349 (US) / +44 208 133 9349 (UK)
email us here


Source: EIN Presswire

Artificial Pancreas Market is poised to grow due to rise in diabetes at a CAGR of 15.2 % till 2023

Artificial Pancreas market information: by control type (threshold suspend device system,) by treatment type and by end users – Global Forecast till 2023

major Key Players are Medtronic, Johnson & Johnson, Beta Bionics,
Biomedical, Admetsys (pipeline product analysis), Animas Corporation, Defymed, dexcom, Insulet, Johnson & Johnson, medtech”

— Market Research Future

PUNE, MAHARASHTRA, INDIA, July 24, 2017 /EINPresswire.com/ — Market Highlights

The artificial pancreas market is chiefly driven by rise in diabetes which is again driven by rise in risk factors such as sedentary lifestyles, unhealthy foods such as fast foods with poor fibre content, high sugar content, lack of exercise etc. Other drivers of anal fissures include the rising screening for diabetes.
The present market is dominated by the threshold suspended device segment and Medtronic’s device series MiniMed leads the market for threshold suspended device segment. The threshold suspend device system act by temporarily suspending infusion of insulin, when the body glucose level falls to a set low threshold.
These systems require frequent patient inputs to avoid a hypoglycaemic event. However, the control-to-range (CTR) system, and control-to-target (CTT) system are expected to gain momentum due to the greater automation, low manual input requirement and their ability to more precisely mimic the working of the natural pancreas system.

Request a Sample Report @ https://www.marketresearchfuture.com/sample_request/3854

Remote monitoring and connected artificial pancreas systems are expected to represent the future of the technology. Several closed loop systems including Inreda's artificial pancreas, Bionic pancreas etc. are in advanced stages of testing for remote monitoring. Another advancement has been the development of the bi-hormonal system which delivers insulin along with another hormone such as glucagon to increase blood glucose levels and more closely mimics the glucose-regulating function of a healthy pancreas than the insulin-only system.

Beta Bionics has developed the iLet Bionic Pancreas system that delivers both insulin and glucagon and is targeted to type 1 diabetes patients; and was developed by Dr. Ed Damiano at the Boston University. Thus, by 2019 products of these key players are anticipated to commercially exist in the market which would increase the market competition, new pricing strategies, assist merger and acquisitions, and geographical expansion strategies.

Major Market Players:

• Medtronic,
• Johnson & Johnson,
• Beta Bionics,
• Bigfoot Biomedical,
• Admetsys (pipeline product analysis),
• Animas Corporation,
• Defymed,
• dexcom,
• Insulet,
• Johnson & Johnson,
• medtech,
• medtronic,
• Semma Therapeutics,
• Tandem Diabetes Care,
• TypeZero Technologies,

Test the market data and market information presented through more than 50 market data tables and figures spread over 80 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Global Artificial pancreas Market Research Report – Forecast to 2023.”

Report Details @ https://www.marketresearchfuture.com/reports/artificial-pancreas-market-3854

Segmentation:
The global Artificial Pancreas market is segmented on the basis of type and end users. Based on type, the market has been segmented as threshold suspend device system, non-threshold suspend device system, control-to-range (CTR) system, and control-to-target (CTT) system. Based on the treatment type, the market has been segmented as insulin only, bi-hormonal, and hybrid. Based on the end users, the market has been segmented as hospitals and clinics, research, and others.

Table of Content

1. Introduction
1.1 Definition
1.2 Scope Of Study
1.2.1 Research Objective
1.2.2 Assumptions & Limitations
1.2.2.1 Assumptions
1.2.2.2 Limitations
1.3 Market Structure:
2. Research Methodology
2.1 Research Process:
2.2 Primary Research
2.3 Secondary Research:
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Macroeconomic Indicators
4. Market Factor Analysis
4.1 Porters Five Forces Model
4.2 Bargaining Power of Suppliers
4.3 Bargaining Power of Buyers
4.4 Threat of New Entrants
4.5 Threat of Substitutes
4.6 Intensity of Rivalry
5. Global Artificial Pancreas Market, By Control Type
Continued…..

Browse Related Statistical Report

Global Insulin Pump Market by type, is projected to grow at a CAGR of 8.4% and is expected to reach US$ 8,520.9 million by 2023. In Global Insulin Pump Market, North America accounted for the largest market share in 2016.

https://www.marketresearchfuture.com/statistical-reports/global-insulin-pump-market-3695

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact:
Akash Anand,
Market Research Future
+1 646 845 9312
Email: akash.anand@marketresearchfuture.com

Akash Anand
Market Research Future
+1-646-845-9349 (US) / +44 208 133 9349 (UK)
email us here


Source: EIN Presswire

LifeLine Software, Inc. Announces Acquisition of Radify Monte Carlo QA Technology from McGill University

Pending Appropriate Regulatory Clearances

LifeLine Software, Inc. Acquires Radify Monte Carlo QA Technology

AUSTIN, TEXAS, UNITED STATES, July 24, 2017 /EINPresswire.com/ — July 24, 2017

Austin, Texas, July 24, 2017 / EINPresswire.com /– LifeLine Software, Inc., a worldwide leader in dosimetric quality assurance tools, is pleased to announce that an agreement has been signed to acquire Radify, a Monte Carlo 3D dose volume QA software technology developed at McGill University in Quebec, Canada.

This acquisition and joint collaboration allows LifeLine Software to bring to market industry-changing 3D dose volume independent dosimetric verification products. LifeLine Software’s integration of the Radify technology will immediately improve accessibility to the significant advantage of Monte Carlo accuracy in clinical settings, specifically for verifying photon, electron, and proton treatment plans.

Monte Carlo is widely recognized as the gold standard dose calculation method. The most challenging clinical cases and complex structures are analyzed with the highest accuracy and confidence. Flexible implementation options and the uncompromised accuracy of a Monte Carlo dose calculation algorithm assist radiation departments to meet their workflow requirements.

"At LifeLine Software, we have always strived to meet and exceed our customers' expectations and to listen to their needs”, said LifeLine Software’s CEO and Co-Founder Craig Laughton. “With the increasing complexity of treatment delivery, the demand for sophisticated quality assurance tools has grown. This acquisition represents our hard work and commitment to our customers to bring the best 3D dose validation tools to the market. We believe the Monte Carlo dose calculation technology provided by the McGill Medical Physics Unit will not only meet our customers' needs but exceed their expectations."

The McGill-affiliated inventors of the Radify technology, Marc-Andre Renaud, François DeBlois and Jan Seuntjens, are experts in Monte Carlo techniques in various medical physics applications, from dosimetry and beam modeling, to treatment planning.

“We are excited to be working with an extraordinary group of medical physicists who have developed a world-class quality assurance software benefiting potentially millions of cancer patients worldwide. Our goal is to receive FDA clearance within the next 18 months” said LifeLine Software’s Co-Founder and President, Jim Dube.

Details of this new technology and our other new 3D Dose Volume QA software package, including RadCalc EPID, the first fully automated Pre-Treatment and 3D In-Vivo Exit dose verification software that provides a complete suite of 3D Dose Volume verification analysis tools and which includes Image Analysis and EPID based measurement functions, are available at our AAPM booth. Demonstrations can be booked directly at the LifeLine Software booth #5091.

About LifeLine Software, Inc.

Founded in 1999 by Craig Laughton (CEO) and Jim Dube (President), Lifeline Software Inc. is a privately held software company headquartered in Tyler, Texas servicing over 2,100 radiation oncology centers worldwide. RadCalc® was developed to provide the most comprehensive QA software program FDA 510(k) cleared to perform independent dosimetric validation calculations including 2D/3D, IMRT, Compensator IMRT, VMAT, 3D collapsed cone convolution/superposition, 3D EPID, 3D Dose Volume-Brachytherapy, Superficial, CyberKnife, Diode, and EDW support.

About McGill University

Founded in Montreal, Quebec, in 1821, McGill is a leading Canadian post-secondary institution. It has two campuses, 11 faculties, 11 professional schools, 300 programs of study and some 40,000 students, including more than 9,400 graduate students. McGill attracts students from nearly 150 countries around the world, its 10,900 international students making up 27% per cent of the student body. Founded in 1979, McGill’s Medical Physics Unit is known for its longstanding CAMPEP-accredited graduate and residency training programs and its research into radiation dosimetry, Monte Carlo, clinical treatment techniques, device development activities and basic radiation research.

Press Contact LifeLine Software, Inc.

Jim Dube
LifeLine Software, Inc.
+1 866.592.1343 ext. 8
jim@lifelinesoftware.com

For more information, visit http://www.lifelinesoftware.com

Jim Dube
LifeLine Software, Inc.
9037142492
email us here


Source: EIN Presswire

Liver Disease Treatment 2017 Global Market Expected to Grow at CAGR Of 11.01% and Forecast to 2021

Wiseguyreports.Com Publish New Market Research Report On-“Liver Disease Treatment 2017 Global Market Expected to Grow at CAGR Of 11.01% and Forecast to 2021”.

PUNE, INDIA, July 24, 2017 /EINPresswire.com/ —

Liver Disease Treatment Market 2017

Executive Summary
Liver is the largest organ of the body and can completely recover from damage. However, continuous strain on the liver, when treatment is delayed, for a prolonged period of time can lead to severe damage to the liver and can even be fatal.
Viral hepatitis is one of the major liver diseases affecting a large number of people across the globe. This is caused by viral infections and spread through contaminated food and water. Poor sanitation facilities in developing countries such as India and China has led to a higher prevalence of the disease in these countries. There has been a rise in healthcare investment in these countries.

The analysts forecast the global liver disease treatment market to grow at a CAGR of 11.01% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global liver disease treatment market for 2017-2021. To calculate the market size, the report considers the sales of vaccines, branded, generic, and off-label drugs in liver disease treatment market.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Request a Sample Report @ https://www.wiseguyreports.com/sample-request/1628856-global-liver-disease-treatment-market-2017-2021

The report, Global Liver Disease Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• F. Hoffmann-la Roche
• Gilead
• GlaxoSmithKline
• Merck

Other prominent vendors
• Bristol-Myers Squibb
• Johnson and Johnson
• Novartis
• Salix Pharmaceuticals
• Vertex Pharmaceuticals

Market driver
• Increase in alcohol-related liver disease
• For a full, detailed list, view our report

Market challenge
• Side-effects of liver disease treatment drugs
• For a full, detailed list, view our report

Market trend
• Rise in awareness
• For a full, detailed list, view our report

Complete Report Details @ https://www.wiseguyreports.com/reports/1628856-global-liver-disease-treatment-market-2017-2021

Table of Contents

PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Market outline

PART 05: Market landscape
• Market overview
• Five forces analysis

PART 06: Pipeline landscape
PART 07: Drug class segmentation
• Global liver disease treatment market by anti-viral drugs
• Global liver disease treatment market by corticosteroids
• Global liver disease treatment market by other drugs
• Global liver disease treatment market by vaccines

PART 08: Market segmentation by disease type
• ARLD
• NAFLD
• Hepatitis
• PBC
• Hemochromatosis

PART 09: Geographical segmentation
• Liver disease treatment market in Americas
• Liver disease treatment market in EMEA
• Liver disease treatment market in APAC

PART 10: Decision framework
PART 11: Drivers and challenges
• Market drivers
• Market challenges

PART 12: Market trends
• Rise in awareness
• Increase in R&D activities for liver cirrhosis medication
• Increasing collaborations and M&A
..…..Continued

For accessing accurate and deep understanding and to gain latest insights and key developments in the area of your interest, we also have a list of conferences in which you will be interested in, for more information, cordially check:
https://www.wiseguyreports.com/conferences

For updating knowledge or for thoroughly understanding various terminologies, we also have vast list of seminars for your reference, for more information cordially check:
https://www.wiseguyreports.com/seminars

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

Global Tissue Banking Market 2017 Share, Trend, Segmentation and Forecast to 2022

Tissue Banking -Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022

PUNE , MAHARASHTRA, INDIA, July 24, 2017 /EINPresswire.com/ — Tissue Banking Industry

Description

Wiseguyreports.Com Adds “Tissue Banking -Market Demand, Growth, Opportunities and Analysis of Top Key Player Forecast To 2022” To Its Research Database

Tissue banks are used to collect the human tissues for the medial and research applications. Tissues banks stores tissues under cryogenic conditions and are further used in drug discovery and development, clinical trials, medical research etc. Human Tissues are widely used in the treatment of the damaged heart muscles, spinal cord injuries. Advancements in the treatment of cell and tissue disorders has created many prospects for tissue banking. Therefore there is huge scope for the growth of the market. The global tissue banking market is anticipated to grow at the CAGR of 11.2% during the period 2017-2022. Increasing demand of the regenerative medicines and advancements in the tissue preservation and in-house sample testing are estimated to augment the growth of the market. Moreover, increasing number of bio banks across the globe, advancements in the medical drug discovery and biopharmaceuticals industry and advancements in the treatment of tissue disorders and cells are also estimated to fuel the growth of the market during the forecast period.

However, there are certain factors that are hindering the growth of the market. Storage and stability issues associated with the tissues and high cost of equipments are estimated to be the major constraints in the growth of the market. Except these restraints, tissue banking market is yet to explore its full potential in the market. Adoption of the advanced cosmetics surgeries and emergence of the automated tissue banking market is estimated to develop numerous expansion opportunities for the growth of the market.

Request for Sample Report @ https://www.wiseguyreports.com/sample-request/1507770-global-tissue-banking-market-research-and-analysis-2015-2022

The global tissue banking market is analyzed on the basis of the products, services and applications. On the basis of the product, market is segmented into equipments, accessories, consumables and media. Equipment market is further divided into freezers, storage systems, thawing equipments, labelling and coding equipments and alarming and monitoring equipments. Further, on the basis of the applications, our market is segmented into bio banking, drug discovery, regenerative medicines, therapeutics and others. And on the basis of the services, our market is bifurcated into processing, quarantine storage, screening, testing, tissue retrieval, screening and others.

Geography Insights
On the basis of the geography, the global tissue banking market is segmented into North America, Asia Pacific, Europe and Rest of the World. North America is estimated to be the leading region in the global tissue banking market. Presence of large number of bio banks that provides tissue samples for therapeutic and research purposes are estimated to be the major factor that is backing the growth of the market. Asia Pacific is estimated to be the fastest growing region during the forecast period owing to increasing biopharmaceuticals market and increasing number of bio banks in the region.

Competitive Insights
Key vendors of the tissue banking market are ABD Serotec, AMS Biotechnology Ltd., Beckman Coulter Inc., Biocision LLC., BioKryo, Biostorage Technologies Inc., Chernobyl Tissue Bank, Custom Biogenic Systems, EMD Millipore Corporation, EPL Archives, Eppendorf AG, Fisher Bioscience Inc., Genzyme Corporation, Organ Recovery Systems Inc., Panasonic Biomedical Sales Europe B.V., Sigma Aldrich Corporation, Taylor-Wharton International LLC., Tecan Group, Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc. and so on. In order to sustain in the market these players adopt various strategies such as mergers, acquisitions, product lunch and geographical expansion. For example: in 2016, Thermo Fisher announced the acquisition of the Affymetric Inc. in a $1.3 billion deal to strengthen its position in the market.

Leave a Query @ https://www.wiseguyreports.com/enquiry/1507770-global-tissue-banking-market-research-and-analysis-2015-2022

Market Segmentation

4.1. GLOBAL TISSUE BANKING MARKET BY PRODUCTS
4.1.1. EQUIPMENT
4.1.1.1. FREEZERS
4.1.1.2. STORAGE SYSTEMS
4.1.1.3. THAWING EQUIPMENT
4.1.1.4. LABELLING AND CODING EQUIPMENT
4.1.1.5. ALARMING AND MONITORING EQUIPMENT
4.1.2. CONSUMABLES
4.1.3. MEDIA
4.1.4. ACCESSORIES
4.2. GLOBAL TISSUE BANKING MARKET BY SERVICES
4.2.1. PROCESSING
4.2.2. QUARANTINE STORAGE
4.2.3. SCREENING
4.2.4. TESTING
4.2.5. TISSUE RETRIEVAL
4.2.6. SCREENING
4.2.7. OTHERS
4.3. GLOBAL TISSUE BANKING MARKET BY APPLICATIONS
4.3.1. BIO BANKING
4.3.2. DRUG DISCOVERY
4.3.3. REGENERATIVE MEDICINES
4.3.4. THERAPEUTICS
4.3.5. OTHERS

Report covers:
• Comprehensive research methodology of Global Tissue Banking Market
• This report also includes detailed and extensive market overview with Analyst insights & key market trends.
• Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the Global Tissue Banking Market
• Insights about market determinants which are stimulating the Global Tissue Banking Market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.

Buy Now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1507770

Continued…

Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here


Source: EIN Presswire

WilliSmart Launches Unique Bag Sealer that Eliminates Food Waste

The new home and kitchen staple is light, portable and also features a USB charging cable.

NEW YORK, NEW YORK, UNITED STATE, July 24, 2017 /EINPresswire.com/ — MAY 10, 2017: Home and kitchen equipments provider, WilliSmart has recently launched a sleek handheld food saving device on Amazon. The highly innovative device is designed to eliminate food waste, thereby allowing people to eat their leftovers later.
Sharing more information about the product, a spokesperson at WilliSmart shared, “At WilliSmart, we believe in designing high quality and user-friendly products. The unique bag sealer is a portable device that enables its user to save money and spend less time preparing freshly cooked meals. Users who are tired of wasting half-full bags of snacks, frozen vegetables and other food items that come in air tight packages can greatly benefit from the bag sealer.”
It must be noted that the WilliSmart bag sealer also helps in minimizing grocery bills. The product is easy to use, fits comfortably in the hand and seals previously opened poly bags effortlessly. Users can simply run the device where they intend to seal the bag and its cordless design enables them to seal quickly and conveniently. The device uses heat and pressure for sealing and binding thermoplastics, resulting in airtight sealing.
Buyers can use the bag sealer to seal a wide variety of poly bags and other bags including chips bag, produce bags, cereal bags, bulk bin bags, baking ingredients, rarely used spices, Lunch bags, clothes for storage, cosmetics and makeup products, fragile souvenirs among other items.
The bag sealer is an excellent option for homeowners who otherwise user clips and rubber bands for storing dry food items and other products. It is easy to charge and offers airtight sealing, thereby minimizing mold formation and spoilage. Users can also maximize their usage of the grocery products and enjoy bacteria free and hygienic food by sealing the remaining or leftover food in poly bags.
WilliSmart also provides buyers with 100% money back guarantee on their bag sealers. Users who are not satisfied with the bag sealer can easily return the product and enjoy 100% refund on the same. Additionally, the WilliSmart Bag Sealer comes with a lifetime guarantee, which makes it’s a highly trusted product. For further details visit http://amzn.to/2uIUARQ!
About WilliSmart
WilliSmart is the leading provider of a wide range of home, dining and kitchen equipments and products. The company is renowned for offering excellent after sales services to its customers across the globe.

Contact:
Company name: WilliSmart
Telephone: 510-240-5427
E-mail: support@willismart.com
Website: http://willismart.com/

William
Willismart
+15102405427
email us here


Source: EIN Presswire

IQ4I Research & Consultancy published a new report on “Urology devices Global Market – Forecast To 2023”

Urology devices are used for diagnosis and treatment of urological diseases, aging population, minimally invasive surgical procedures are driving the market.

Urology Devices Global Market estimated to be worth $33,966.5 million by 2023”

— IQ4I Analyst

BOSTON, MASSACHUSETTS, U.S., July 24, 2017 /EINPresswire.com/ — Urology is a branch of medicine that focuses on diagnosis, medical and surgical treatment of diseases associated with urinary tract and male & female reproductive systems. The main function of urogenital system is to eliminate wastes from the body, regulate blood volume and blood pressure, control levels of electrolytes and metabolites, regulate blood pH and reproduction. Abnormalities, improper function or congenital or acquired dysfunction of urogenital system leads to various urology diseases like kidney disease, urinary stones, benign prostatic hyperplasia, urinary incontinence, pelvic organ prolapse, urological cancer and erectile dysfunction etc. These urology diseases are diagnosed and treated through biochemical blood tests, urinalysis, pharmaceutical medications and traditional open and minimally invasive surgical methods.

Minimally invasive surgical methods using various devices like endoscopy, urodynamic systems, dialysis devices, lithotripsy etc is gaining momentum in recent times, since, these devices eliminate the need of traditional open surgeries with various advantages like minimal incisions, low healthcare costs, quick recovery times and shorter hospital stays.

According to IQ4I analysis, the Urology devices global market is expected to grow at mid single digit CAGR to reach $33,966.5 million by 2023. Increase in aging population and subsequent rise in incidence of kidney and urology diseases and increased demand for minimal invasive surgical procedures are some of the factors driving the urology devices market growth. Favorable reimbursement policies, rising awareness of urology device due to faster recovery time and reduced treatment care and market expansion opportunities in emerging countries are few opportunities for the urology devices market. However, patient safety risks due to chances of infections and other complications while using urology device and lack of skilled professionals in handling urology devices are expected to hamper the market growth.

The Urology devices market is segmented based on their products, applications, end-users, and geography. The products segment is further segmented into urology endoscopes, dialysis devices, stone management devices, urodynamic systems, benign prostatic hyperplasia devices, incontinence care devices, erectile dysfunction devices, nephrostomy devices and urology screeners. Dialysis devices segment accounted largest share, due to technological advancements, increasing awareness, increased demand etc.

Based on applications, the urology device market is segmented into kidney disease, urinary stones, benign prostatic hyperplasia, urinary incontinence, pelvic organ prolapse, urological cancer, erectile dysfunction and others. Kidney disease accounts the largest share, due to miniaturization of device and fast turn-around time for analysis.

Based on the end-users type, the market is segmented into hospitals, home healthcare, clinics, ambulatory surgical centers, academic and diagnostic laboratories and others. Hospitals segment occupied the largest share due to rising incidence of urology disorders in aging population and increasing demand for technically advanced products by the end-users.

Based on geography the urology devices global market is divided into North America, Europe, Asia-Pacific and Rest of the world. Europe region commanded the largest market share. However, Asia-Pacific region is expected to grow at the highest due to rising awareness, higher economic growth, large patient pool and rising aged population.

Technological advancements in urology devices market includes lithotripsy devices, robotic assisted and laser associated urology devices. Present trend in this market is performing minimally invasive laparoscopic surgeries for easy visualization of intricate organs and performing surgeries with fewer incisions in accurate and precise manner. For instance, Massachusetts Institute of Technology (U.S.) are currently working in development of new video processing system which has the ability in identifying and recording different stages of laparoscopic surgeries assisting urologists and researchers to understand and carry out relevant studies. In May 2017, Intuitive Surgical Inc (U.S.) received FDA clearance for its Da Vinci X robotic surgical system which enables in performing optimized, focused-quadrant surgery procedures like prostatectomy, partial nephrectomy and benign hysterectomy. The system features flexible port placement, 3D digital optics with set-up technology that uses voice and laser guidance, drape design for simplifying surgery procedure.

The Urology devices global market is fragmented and is growing at a moderate rate, key players like Fresenius Kabi (Germany), Baxter International Inc (U.S.), Nipro Corporation (Japan) and Olympus Corporation (Japan) occupied major share. Companies in this market are coming up with innovative technologies and devices for entering or maintaining their leadership position in different sectors of urology device market. In March 2017, Signostics (U.S.) introduced Uscan device in U.S. market which uses cutting-edge, hand-held ultrasound technology for bladder and kidney care through providing industry leading accuracy in the measurement of bladder volume residual.

Major players in Urology devices market are B Braun Melsungen AG (Germany), Boston Scientific Corporation (U.S.), Cook Medical (U.S.), Coloplast (Denmark), Nipro Corporation (Japan), Fresenius Medical Care AG & Co. KGaA (Germany), Baxter International, Inc. (U.S.), C.R. Bard (Inc U.S.), Olympus Corporation (Japan) and KARL STORZ GmbH & Co. KG (Germany).

Some of the other companies operating in Urology devices are Richard WOLF GmbH (Germany), Dornier Medtech GmbH (Germany), Escad Medical (Germany), Maxer (Germany), Laborie (Canada), Dantec Medical (U.K.), Albyn Medical (U.K.), Medical Measurement Systems B.V. (Netherlands), NxStage Medical Inc (U.S.), Dialife S.A. (Switzerland), Allmed Medical (London), China Chengdu Wesley Biotech Co., Ltd (China), Outset Medical (U.S.), etc.

Mr. Sattish Biruddukota
IQ4I Research & Consultancy Pvt Ltd.,
+91-80-60500229
email us here


Source: EIN Presswire

Intermountain Medical Center Honored For Stroke Care Excellence

Intermountain Medical Center has received the American Heart Association/American Stroke Association’s 2017 Get With The Guidelines-Stroke Gold Plus Achievement Award — the highest possible award in the category — for reaching an aggressive goal of treati

Being honored for excellent patient care is the best recognition a hospital can receive.”

— Megan Donohue, MD, Intermountain Medical Center Neurosciences Institute

SALT LAKE CITY, UT, USA , July 24, 2017 /EINPresswire.com/ — Intermountain Medical Center has received the American Heart Association/American Stroke Association’s 2017 Get With The Guidelines-Stroke Gold Plus Achievement Award — the highest possible award in the category — for reaching an aggressive goal of treating stroke patients with greater than 85 percent compliance to core standard levels of care for 24 consecutive months.

In addition to the Stroke Gold Plus Quality Achievement Award, Intermountain Medical Center also received the Target Stroke Honor Roll Elite Plus, which, is the highest possible award in its category. The award signifies the hospital achieves time to treatment with IV thrombolytic therapy in 60 minutes or less in more than 75 percent of patients, and within 45 minutes in more than 50 percent of eligible patients.

"In my opinion, being honored for excellent patient care is the best recognition a hospital can receive. We work hard every day to improve our treatment times so we can keep providing the best possible care to our stroke patients,” says Megan Donohue, MD, medical director of Stroke Services for the Intermountain Medical Center Neurosciences Institute.

Get with the Guidelines is a quality improvement initiative of the American Heart Association and American Stroke Association to improve quality of care and outcomes for stroke patients.

Get with the Guidelines puts the expertise of the American Heart Association and American Stroke Association to work for hospitals nationwide, helping hospital care teams ensure the care provided to patients is aligned with the latest research-based guidelines based on the latest scientific evidence.

"We have an amazing team of individuals devoted to caring for stroke patients here at Intermountain Medical Center, and each one of them has played an important role in achieving this award,” says Heidi Hafen, Stroke Program coordinator for the Intermountain Medical Center Neurosciences Institute.

Get with the Guidelines is a quality improvement initiative of the American Heart Association and American Stroke Association to improve quality of care and outcomes for stroke patients.

Get with the Guidelines puts the expertise of the American Heart Association and American Stroke Association to work for hospitals nationwide, helping hospital care teams ensure the care provided to patients is aligned with the latest research-based guidelines based on the latest scientific evidence.

In treating a stroke, time is brain: For every minute blood flow is interrupted, almost two million brain cells die. If appropriate treatment is given quickly, research shows patients have better outcomes and less disability. At Intermountain Medical Center, the time to treatment from when the patient arrives at the hospital is approximately 20 minutes faster than the national average.

Jess Gomez
Intermountain Medical Center
801-507-7455
email us here


Source: EIN Presswire

Arizona Mesothelioma Victims Center Now Urges a Diagnosed US Navy Veteran in Arizona To Call Them About Compensation and Why Its Vital They Hire One of The Nation's Most Skilled Lawyers

The incredibly skilled mesothelioma attorneys we suggest recognize how important it is for a diagnosed person with mesothelioma to get properly compensated-so do we”

— Arizona Mesothelioma Victims Center

NEW YORK, NEW YORK, USA, July 24, 2017 /EINPresswire.com/ — The Arizona Mesothelioma Victims Center says, "We are urging a US Navy Veteran who has recently been diagnosed with mesothelioma in Arizona to call us anytime at 800-714-0303 about financial compensation as well as why it is incredibly vital to hire one of the nation's most experienced mesothelioma attorneys to get the best settlement outcome." http://Arizona.MesotheliomaVictimsCenter.Com

A mesothelioma compensation claim for a US Navy Veteran in Arizona can potentially involve hundreds of thousands of dollars or more, but if the diagnosed person hires a local car accident lawyer or a mesothelioma marketing law firm there is not much anyone can do to help terminate the lawyers or law firm if they turn out to be less than competent. To illustrate the point-In the group's opinion a substandard mesothelioma compensation outcome would be something like net 350,000 to the diagnosed US Navy Veteran who was exposed as a machinist or boiler technician while in the US Navy. The group believes the net compensation award could be as much as $750,000 or more if the person had hired one of the nation’s most qualified and experienced mesothelioma attorneys as they would like to explain anytime at 800-714-0303. http://Arizona.MesotheliomaVictimsCenter.Com

Before a US Navy Veteran with confirmed mesothelioma in Arizona or their family hires a lawyer/law firm to assist with a mesothelioma compensation claim they are urged to call the Arizona Mesothelioma Victims Center for some clarity at 800-714-0303. The group's number one goal is a person with mesothelioma in Arizona receiving the best possible compensation and they are more than happy to suggest or recommend some of the nation's most skilled mesothelioma attorneys anytime to a diagnosed person or their family who will almost always call the diagnosed person-immediately.

"The incredibly skilled mesothelioma attorneys we suggest recognize how important it is for a diagnosed person with mesothelioma to get properly compensated-so do we." http://Arizona.MesotheliomaVictimsCenter.Com

For the best possible mesothelioma treatment options in Arizona the Arizona Mesothelioma Victims Center strongly recommends the following heath care facilities with the offer to help a diagnosed victim, or their family get to the right physicians at each hospital.

* The Mayo Clinic Phoenix/Scottsdale, Arizona: http://www.mayoclinic.org/patient-visitor-guide/arizona
* The University of Arizona Medical Center Tucson, Arizona:
http://azcc.arizona.edu/profile/linda-garland

The Arizona Mesothelioma Victims Center would like to emphasize theirs is a statewide initiative available to a diagnosed victim anywhere in Arizona including communities such as Phoenix, Tucson, Mesa, Chandler, Glendale, Gilbert, Tempe. Peoria, or Prescott. http://Arizona.MesotheliomaVictimsCenter.Com

High-risk work groups for exposure to asbestos in Arizona include US Navy Veterans, power plant workers, manufacturing workers, plumbers, nuclear power plant workers, electricians, auto mechanics, machinists, or construction workers. Typically, these high-risk workers were exposed to asbestos in the 1950’s, 1960’s, 1970’s, or 1980’s.

The states indicated with the highest incidence of mesothelioma include Maine, Massachusetts, Connecticut, Maryland, New Jersey, Pennsylvania, Ohio, West Virginia, Virginia, Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon. Mesothelioma also happens in Arizona. http://Arizona.MesotheliomaVictimsCenter.com

For more information about mesothelioma please refer to the National Institutes of Health’s web site related to this rare form of cancer: http://www.nlm.nih.gov/medlineplus/mesothelioma.html

Michael Thomas
Arizona Mesothelioma Victims Center
800-714-0303
email us here


Source: EIN Presswire